HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Today's Posts

 
 
Thread Tools Display Modes
Prev Previous Post   Next Post Next
Old 10-24-2013, 10:53 AM   #15
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Re: Pattern of recurrence of early bc differs by intrinsic subtype & proliferation in

I like the idea of the booster.

After looking at Hopeful's prior conversation I see perhaps two higher risk times, one about a 2-2 1/2 year interval, another at 5-6 years with ER+, Her2+.

I love the idea of the Herceptin injections as boosters. Do we really need a clinical trial? Almost all have had an entire year of Herceptin infusions. For stage 1-3 who remain as NED this has been for prevention. To receive an injection booster at 18 months, then 24 mths, 48 mths and 60 mths for ER+, Her2 patients should be something left to the discretion of the oncologist and patient.

"Modern" medicine will never achieve personalized care if the FDA has to approve & micromanage everything based on clinical trials for the good of the group, and not the individual.

Last edited by 'lizbeth; 10-24-2013 at 10:54 AM.. Reason: typo(s)
'lizbeth is offline   Reply With Quote
 


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 05:43 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter